HUMAN / 24 OCTOBER 2026 / FROZEN POLICY 2026-10-24.1

What made it, what did not, and why

Every mapped nomination has cancer RNA/IHC occurrence, its current decision, normal evidence, and curated biology or a clear coverage gap. RNA occurrence uses native pTPM, normal observations retain TPM/nTPM, and cohorts remain separate.

A retained label is a research-screen pass. New literature flags 37 retained genes; ABCC11 and MAGEC2 need urgent normal neural-protein review before target use. Clinical outcomes are individually reviewed for selected targets, not all 2,540 genes. Missing evidence never establishes safety.